Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

chronic myelocytic leukemia

5

Unknown

2,578

Pain

614

Cancer

592

Hypertension

567

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Previously Marketed

5

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

5

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1957

5

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

5

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

5

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

5

PUBCHEM

5

CAS

4

NCI_THESAURUS

3

NDF-RT

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

VARIOUS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

THERAPEUTIC RADIOPHARMACEUTICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER THERAPEUTIC RADIOPHARMACEUTICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Various therapeutic radiopharmaceuticals

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

4

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 5 of 5 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

PHOSPHATE ION P-32

N27ADP50ER

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1957

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

chronic lymphocytic leukemia

chronic myelocytic leukemia

polycythemia vera

P-32 is a radioactive isotope of phosphorus with a half-life of 14.29 days. Radioactive decay of P-32 produces beta-particles (electrons) which are able to penetrate tissue at a range of 3-8 mm. Phosphate ion P-32 has many applications in medicine an...

d biology. P32 sodium phosphate was approved by the FDA for the treatment of polycythemia vera, chronic myelocytic leukemia, and chronic lymphocytic leukemia. P32-phosphate may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases. As metabolic uptake of phosphorus is selectively increased in malignant tissues, P-32 was also used for cancer diagnostics.

SODIUM PHOSPHATE P-32, UNSPECIFIED

FEB963GEFV

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1957

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

chronic lymphocytic leukemia

chronic myelocytic leukemia

polycythemia vera

P-32 is a radioactive isotope of phosphorus with a half-life of 14.29 days. Radioactive decay of P-32 produces beta-particles (electrons) which are able to penetrate tissue at a range of 3-8 mm. Phosphate ion P-32 has many applications in medicine an...

d biology. P32 sodium phosphate was approved by the FDA for the treatment of polycythemia vera, chronic myelocytic leukemia, and chronic lymphocytic leukemia. P32-phosphate may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases. As metabolic uptake of phosphorus is selectively increased in malignant tissues, P-32 was also used for cancer diagnostics.

PHOSPHORIC ACID P-32

N9H3ZTX0BG

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1957

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

chronic lymphocytic leukemia

chronic myelocytic leukemia

polycythemia vera

P-32 is a radioactive isotope of phosphorus with a half-life of 14.29 days. Radioactive decay of P-32 produces beta-particles (electrons) which are able to penetrate tissue at a range of 3-8 mm. Phosphate ion P-32 has many applications in medicine an...

d biology. P32 sodium phosphate was approved by the FDA for the treatment of polycythemia vera, chronic myelocytic leukemia, and chronic lymphocytic leukemia. P32-phosphate may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases. As metabolic uptake of phosphorus is selectively increased in malignant tissues, P-32 was also used for cancer diagnostics.

SODIUM PHOSPHATE P-32

O181101B5G

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1957

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

chronic lymphocytic leukemia

chronic myelocytic leukemia

polycythemia vera

P-32 is a radioactive isotope of phosphorus with a half-life of 14.29 days. Radioactive decay of P-32 produces beta-particles (electrons) which are able to penetrate tissue at a range of 3-8 mm. Phosphate ion P-32 has many applications in medicine an...

d biology. P32 sodium phosphate was approved by the FDA for the treatment of polycythemia vera, chronic myelocytic leukemia, and chronic lymphocytic leukemia. P32-phosphate may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases. As metabolic uptake of phosphorus is selectively increased in malignant tissues, P-32 was also used for cancer diagnostics.

CHROMIC PHOSPHATE P-32

QHO02LZ4H2

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1957

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

chronic lymphocytic leukemia

chronic myelocytic leukemia

polycythemia vera

P-32 is a radioactive isotope of phosphorus with a half-life of 14.29 days. Radioactive decay of P-32 produces beta-particles (electrons) which are able to penetrate tissue at a range of 3-8 mm. Phosphate ion P-32 has many applications in medicine an...

d biology. P32 sodium phosphate was approved by the FDA for the treatment of polycythemia vera, chronic myelocytic leukemia, and chronic lymphocytic leukemia. P32-phosphate may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases. As metabolic uptake of phosphorus is selectively increased in malignant tissues, P-32 was also used for cancer diagnostics.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1